JP2007536311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536311A5 JP2007536311A5 JP2007511998A JP2007511998A JP2007536311A5 JP 2007536311 A5 JP2007536311 A5 JP 2007536311A5 JP 2007511998 A JP2007511998 A JP 2007511998A JP 2007511998 A JP2007511998 A JP 2007511998A JP 2007536311 A5 JP2007536311 A5 JP 2007536311A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- agents
- present
- pharmaceutical
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0409921.4A GB0409921D0 (en) | 2004-05-04 | 2004-05-04 | Organic compounds |
| PCT/EP2005/004783 WO2005105727A1 (en) | 2004-05-04 | 2005-05-03 | Crth2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007536311A JP2007536311A (ja) | 2007-12-13 |
| JP2007536311A5 true JP2007536311A5 (enExample) | 2008-06-19 |
Family
ID=32482645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511998A Pending JP2007536311A (ja) | 2004-05-04 | 2005-05-03 | Ｃｒｔｈ２受容体アンタゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080269335A1 (enExample) |
| EP (1) | EP1756032A1 (enExample) |
| JP (1) | JP2007536311A (enExample) |
| KR (1) | KR20070015562A (enExample) |
| CN (1) | CN1950323A (enExample) |
| AU (1) | AU2005238199B2 (enExample) |
| BR (1) | BRPI0510606A (enExample) |
| CA (1) | CA2563454A1 (enExample) |
| GB (1) | GB0409921D0 (enExample) |
| MX (1) | MXPA06012664A (enExample) |
| RU (1) | RU2006142738A (enExample) |
| WO (1) | WO2005105727A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| JP5208510B2 (ja) | 2004-11-23 | 2013-06-12 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体 |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| JP5155171B2 (ja) | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| EP1963259B1 (en) * | 2005-12-15 | 2012-02-15 | AstraZeneca AB | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| BRPI0907364A2 (pt) | 2008-02-01 | 2015-07-14 | Amira Pharmaceuticals Inc | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| AU2009266793B2 (en) | 2008-07-03 | 2012-12-20 | Brickell Biotech, Inc. | Antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| WO2011002814A2 (en) * | 2009-06-30 | 2011-01-06 | Ligand Pharmaceuticals Inc. | Biaryl oxyacetic acid compounds |
| EP2461809A4 (en) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES |
| EP2462110A4 (en) | 2009-08-05 | 2013-04-03 | Panmira Pharmaceuticals Llc | DP2 ANTAGONIST AND USES THEREOF |
| AU2011203649A1 (en) | 2010-01-06 | 2012-06-14 | Brickell Biotech, Inc. | DP2 antagonist and uses thereof |
| JP5800898B2 (ja) * | 2010-07-05 | 2015-10-28 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| RU2014129613A (ru) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2 |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| DK3307262T3 (da) | 2015-06-15 | 2021-08-09 | Nmd Pharma As | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI794369B (zh) | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TW201927738A (zh) | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| WO2020233713A1 (zh) * | 2019-05-22 | 2020-11-26 | 石药集团中奇制药技术（石家庄）有限公司 | 杂环化合物及其盐的应用 |
| US12415771B2 (en) | 2019-06-19 | 2025-09-16 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2039490A1 (de) * | 1970-08-08 | 1972-02-24 | Agfa Gevaert Ag | Fotografisches farbkupplerhaltiges Material |
| DE2039489C3 (de) * | 1970-08-08 | 1979-08-09 | Agfa-Gevaert Ag, 5090 Leverkusen | Farbfotografisches Aufzeichnungsmaterial |
| CH585687A5 (enExample) * | 1972-08-24 | 1977-03-15 | Ciba Geigy Ag | |
| DE2503223A1 (de) * | 1974-02-05 | 1975-08-07 | Sandoz Ag | Verfahren zur herstellung neuer carbocyclischer verbindungen |
| FR2567514B1 (fr) * | 1984-07-13 | 1987-08-28 | Najer Henry | Nouveaux ether-oxydes derives de cyclopropylphenols |
| KR100340273B1 (ko) * | 1997-10-14 | 2002-06-14 | 야마모토 카즈모토 | 비페닐-5-알칸산 유도체 및 이의 용도 |
| JPH11263752A (ja) * | 1998-01-12 | 1999-09-28 | Honshu Chem Ind Co Ltd | ヒドロ芳香族オキシ酢酸ｔ―ブチルエステル |
| JP2002516305A (ja) * | 1998-05-12 | 2002-06-04 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン抵抗性および高血糖症の治療に有用な２，３，５−置換ビフェニル |
| US6867320B2 (en) * | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
| PT1477472E (pt) * | 2002-02-21 | 2009-03-17 | Asahi Kasei Pharma Corp | Derivado de ácido fenilalcanóico substituído e sua utilização |
| AU2004232682B2 (en) * | 2003-03-28 | 2006-12-07 | Eli Lilly And Company | Isoquinoline-5-sulfonic acid amides as inhibitors of Akt (protein kinase B) |
| SE0301009D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| KR20060079190A (ko) * | 2003-08-14 | 2006-07-05 | 아사히 가세이 파마 가부시키가이샤 | 치환 아릴알칸산 유도체 및 그의 용도 |
-
2004
- 2004-05-04 GB GBGB0409921.4A patent/GB0409921D0/en not_active Ceased
-
2005
- 2005-05-03 JP JP2007511998A patent/JP2007536311A/ja active Pending
- 2005-05-03 BR BRPI0510606-0A patent/BRPI0510606A/pt not_active IP Right Cessation
- 2005-05-03 CA CA002563454A patent/CA2563454A1/en not_active Abandoned
- 2005-05-03 MX MXPA06012664A patent/MXPA06012664A/es not_active Application Discontinuation
- 2005-05-03 AU AU2005238199A patent/AU2005238199B2/en not_active Ceased
- 2005-05-03 CN CNA2005800143644A patent/CN1950323A/zh active Pending
- 2005-05-03 US US11/568,464 patent/US20080269335A1/en not_active Abandoned
- 2005-05-03 KR KR1020067023085A patent/KR20070015562A/ko not_active Withdrawn
- 2005-05-03 EP EP05741318A patent/EP1756032A1/en not_active Withdrawn
- 2005-05-03 RU RU2006142738/04A patent/RU2006142738A/ru not_active Application Discontinuation
- 2005-05-03 WO PCT/EP2005/004783 patent/WO2005105727A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007536311A5 (enExample) | ||
| Das et al. | A survey of the structures of US FDA approved combination drugs | |
| Cui et al. | Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction | |
| CN109640981A (zh) | 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途 | |
| NO340679B1 (no) | Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer | |
| CL2004001170A1 (es) | Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v | |
| JP2006508953A5 (enExample) | ||
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| WO2006058249A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| DE60030844D1 (de) | Kombinationen von formoterol und tiotropium-salz | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2004105694A3 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
| JP2015524444A5 (enExample) | ||
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| JP2005515966A5 (enExample) | ||
| EE05404B1 (et) | Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nhtud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| JP2005537268A5 (enExample) | ||
| WO2006008639A8 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| JP2006516571A5 (enExample) | ||
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |